Mr. Arun Menawat reports

PROFOUND'S INTRODUCTION OF NEW REAL-TIME INTERVENTIONAL MRI SOFTWARE PAVING THE WAY FOR FULL ‘TULSA DAYS'

Profound Medical Corp. has introduced its latest treatment delivery consol (TDC) software.

The new TDC software, which is being deployed across Profound's Tulsa-Pro installed base, further builds upon previously implemented Tulsa-AI modules focused on increasing procedural efficiency and physician experience, while reducing planning complexity. It brings two new focuses of features that are designed to even further increase Tulsa procedure efficiency and support the ability to regionally ablate tissue for a variety of prostate indications:

• Real-time iMRI control, putting the surgeon more squarely in the driver's seat of Tulsa-Pro's supervised robotic autonomy;
• Physician-requested improvements to the user interface and hardware control.

"Today, a few Tulsa physicians already report being able to perform up to four Tulsa procedures per day," said Arun Menawat, Profound's chief executive officer and chairman. "Many Tulsa physicians also report that Tulsa-Pro is already one of the least stressful devices they use. The objective of introducing the latest TDC software is to further increase ease of use and reduce overall procedure times, and provide what we believe is a road map that would allow surgeons to achieve up to six procedures per day."

Dr. Menawat continued: "Tulsa is the only prostate treatment modality that deploys supervised robotic autonomy, meaning it executes predefined and/or artificial-intelligence-driven tasks independently. This compares to competitive 'master-slave' robotic systems that instead rely on direct, real-time human hand movement and control. Putting physicians more squarely in the driver's seat of Tulsa-Pro's autonomous robotics via this software upgrade will further enhance their ability to deliver consistent, highly personalized prostate ablation based on each patient's unique anatomy and disease. In the future, it may also give us an even stronger competitive advantage as prostate surgery advances to its next potential frontier, including incisionless telesurgery."

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company's flagship platform, Tulsa-Pro, enables MRI-guided, incision-free prostate ablation. Physicians use the Tulsa procedure to see, ablate and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care-from whole-gland to subtotal, hemi, multifocal and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumours and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay and faster recovery -- and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical's technologies are approved across major global markets. Tulsa-Pro is cleared by the FDA in the United States for transurethral ultrasound ablation (Tulsa) of prostate tissue. In addition, Tulsa-Pro is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the United Arab Emirates. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy -- expanding access to precise, personalized and incision-free treatment options worldwide.

We seek Safe Harbor.